MA44066A - Composés sulfonamides de dihydroquinoline d'alcynyle - Google Patents

Composés sulfonamides de dihydroquinoline d'alcynyle

Info

Publication number
MA44066A
MA44066A MA044066A MA44066A MA44066A MA 44066 A MA44066 A MA 44066A MA 044066 A MA044066 A MA 044066A MA 44066 A MA44066 A MA 44066A MA 44066 A MA44066 A MA 44066A
Authority
MA
Morocco
Prior art keywords
alcynyl
dihydroquinoline
sulphonamide compounds
sulphonamide
compounds
Prior art date
Application number
MA044066A
Other languages
English (en)
Inventor
Thomas Dineen
Karina R Vaida
Matthew Weiss
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA44066A publication Critical patent/MA44066A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA044066A 2015-12-18 2016-12-19 Composés sulfonamides de dihydroquinoline d'alcynyle MA44066A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562269533P 2015-12-18 2015-12-18

Publications (1)

Publication Number Publication Date
MA44066A true MA44066A (fr) 2018-10-24

Family

ID=57758770

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044066A MA44066A (fr) 2015-12-18 2016-12-19 Composés sulfonamides de dihydroquinoline d'alcynyle

Country Status (8)

Country Link
US (1) US10729684B2 (fr)
EP (1) EP3390393A1 (fr)
JP (1) JP6985271B2 (fr)
AU (1) AU2016369653B2 (fr)
CA (1) CA3008485C (fr)
MA (1) MA44066A (fr)
MX (1) MX378012B (fr)
WO (1) WO2017106872A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008995A2 (pt) 2018-12-26 2021-08-10 Raqualia Pharma Inc. derivados heterocíclicos como bloqueadores de nav1.7 e nav1.8
US12533341B2 (en) 2019-12-11 2026-01-27 Duke University Small molecule inhibitors of voltage-gated sodium channel 1.7 and methods of using same
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
JP7879815B2 (ja) * 2020-06-10 2026-06-24 アムジエン・インコーポレーテツド ヘテロアルキルジヒドロキノリンスルホンアミド化合物
JP7880201B2 (ja) * 2020-06-10 2026-06-25 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
EP4385978A4 (fr) * 2021-08-12 2025-08-13 Tyk Medicines Inc Composé polycyclique et son utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
WO2010045197A1 (fr) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
WO2013122897A1 (fr) * 2012-02-13 2013-08-22 Amgen Inc. Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
US9212182B2 (en) * 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors

Also Published As

Publication number Publication date
WO2017106872A1 (fr) 2017-06-22
EP3390393A1 (fr) 2018-10-24
CA3008485A1 (fr) 2017-06-22
JP2018537505A (ja) 2018-12-20
CA3008485C (fr) 2023-08-01
AU2016369653B2 (en) 2021-02-04
US10729684B2 (en) 2020-08-04
US20180369226A1 (en) 2018-12-27
AU2016369653A1 (en) 2018-07-05
MX2018007511A (es) 2018-09-18
MX378012B (es) 2025-03-10
JP6985271B2 (ja) 2021-12-22

Similar Documents

Publication Publication Date Title
IL273786A (en) New sulfonamide carboxamide compounds
HUE057414T2 (hu) Új szulfonamid karboxamid vegyületek
IL272555A (en) New sulfonamide carboxamide compounds
IL272550A (en) New sulfonamide carboxamide compounds
EP3720430A4 (fr) Composés benzocarbonyle
EP3691623A4 (fr) Composés de benzosulfonyle
EP3558322A4 (fr) Composés benzyl-amide phosphodiamide antiviraux
EP3532069A4 (fr) Composés aryl-amide phosphodiamide antiviraux
MA45116A (fr) Composés hétérocycliques comme immunomodulateurs
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
EP3474845A4 (fr) Composés immunomodulateurs
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA42293A (fr) Composés antibactériens
MA45148A (fr) Composés de carfilzomib pégylés
EP3464336A4 (fr) Composés
EP3728289A4 (fr) Composés optimisés
MA44065A (fr) Composés sulfonamides de dihydroquinoline d'alkyle
EP3405455A4 (fr) Composés de 2-oxindole
EP3713941A4 (fr) Composés de pyrazolopyridinone
MA51221A (fr) Composés de pyrazolopyridinone
EP3344280A4 (fr) Formation d'os
MA48946A (fr) Composés
EP3325497A4 (fr) Composés quinstatine
EP3487840A4 (fr) Composés de cyclohexyle benzamide
EP3365375A4 (fr) Composés d'administration intracellulaire